title: Cytokines in Sjogren's syndrome: potential therapeutic targets.
abstract: The dysregulated cytokine network in Sjögren's Syndrome (SS) is reflected by local and systemic overexpression of pro-inflammatory cytokines and absent or low levels of anti-inflammatory cytokines. To date, the use of cytokine based therapies in SS has been disappointing. Oral administration of low dose interferon (IFN) alpha showed inconsistent efficacy in various studies and failed to achieve the primary endpoint in a pivotal randomised controlled trial. Similarly, neither of the two tumour necrosis factor (TNF)-alpha blockers tested (etanercept and infliximab) showed efficacy in placebo controlled trials. Although the rationale for low dose oral IFN treatment has not been firmly established, TNF blockade was based on solid preclinical data. Therefore, the reason for the lack of efficacy is unclear, but recent data suggest that unexpected biological effects of TNF antagonists may have contributed to this. Cytokines, given their central role in the pathogenesis of SS, remain attractive targets for future treatments, despite the disappointing early results. Inflammatory cytokines are obvious candidates, and agents against several of them are available or under development for other autoimmune diseases similar to SS. New candidate cytokines such as IL-17 and IL-12 and/or IL-23 may provide promising targets for SS. Additionally, as an alternative to systemic treatment, which has the risk of potentially severe side effects, the use of local cytokine directed therapy should be explored.
authors.affiliation: Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, 10 Center Drive, Bethesda, MD 20892-1190, USA. roeschern@mail.nih.gov
authors.forename: Nienke
authors.initials: N
authors.lastname: Roescher
authors.forename: Paul P
authors.initials: PP
authors.lastname: Tak
authors.forename: Gabor G
authors.initials: GG
authors.lastname: Illei
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha
references.citation: Lancet. 2008 Mar 22;371(9617):987-97
references.pmid: 18358926
references.citation: Arthritis Rheum. 2010 Feb;62(2):542-52
references.pmid: 20112381
references.citation: Immunity. 2000 Nov;13(5):715-25
references.pmid: 11114383
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5
references.pmid: 16477017
references.citation: Arthritis Rheum. 2007 Dec;56(12):3995-4004
references.pmid: 18050196
references.citation: Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):109-16
references.pmid: 16898079
references.citation: J Immunol. 2008 Aug 15;181(4):2898-906
references.pmid: 18684981
references.citation: Ann Rheum Dis. 2008 Oct;67(10):1437-43
references.pmid: 18198195
references.citation: Br J Rheumatol. 1993 Jan;32(1):52-4
references.pmid: 8422560
references.citation: Am J Vet Res. 2005 Jan;66(1):164-76
references.pmid: 15691053
references.citation: Arthritis Rheum. 2008 Mar;58(3):734-43
references.pmid: 18311793
references.citation: Arthritis Rheum. 2003 Aug 15;49(4):585-93
references.pmid: 12910567
references.citation: Hum Gene Ther. 2003 Nov 20;14(17):1605-18
references.pmid: 14633403
references.citation: Oral Dis. 2009 Nov;15(8):519-26
references.pmid: 19519622
references.citation: Am J Pathol. 2009 Sep;175(3):1167-77
references.pmid: 19700754
references.citation: Arthritis Rheum. 2004 Apr;50(4):1270-6
references.pmid: 15077311
references.citation: Genes Immun. 2009 Jun;10(4):285-96
references.pmid: 19404300
references.citation: Arthritis Rheum. 2005 Sep;52(9):2740-50
references.pmid: 16142737
references.citation: Arthritis Rheum. 2009 Jun;60(6):1785-96
references.pmid: 19479852
references.citation: Br J Rheumatol. 1990 Feb;29(1):50-2
references.pmid: 2306573
references.citation: Arthritis Rheum. 2001 Oct;44(10):2371-5
references.pmid: 11665979
references.citation: J Interferon Cytokine Res. 1998 Apr;18(4):255-62
references.pmid: 9568728
references.citation: Clin Exp Rheumatol. 1996 Jul-Aug;14(4):367-71
references.pmid: 8871834
references.citation: Curr Opin Investig Drugs. 2008 May;9(5):515-22
references.pmid: 18465662
references.citation: Eur J Immunol. 2008 Apr;38(4):1058-64
references.pmid: 18350548
references.citation: Curr Opin Immunol. 2006 Dec;18(6):670-5
references.pmid: 17010592
references.citation: Arthritis Rheum. 2004 Jul;50(7):2240-5
references.pmid: 15248223
references.citation: Ann Rheum Dis. 2006 Feb;65(2):195-200
references.pmid: 15975969
references.citation: J Interferon Cytokine Res. 1999 Aug;19(8):943-51
references.pmid: 10476942